World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
42010
World Ranking
12932
National Ranking
6611

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

David E. Moller is affiliated with Eli Lilly in the United States. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Within these broader disciplines, their work has focused notably on Molecular Biology, Physiology, Surgery, Endocrinology, Diabetes and Metabolism, and Genetics.

The scientist's main topics of study include Metabolism, Diabetes, and Cancer; Pancreatic function and diabetes; Liver Disease Diagnosis and Treatment; Diet, Metabolism, and Disease; Peroxisome Proliferator-Activated Receptors; Adipose Tissue and Metabolism; and Diabetes Treatment and Management.

David E. Moller has contributed to a range of scientific publications, with recent papers including:

  • "Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes" (2020, Diabetes Obesity and Metabolism)
  • "Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action" (2021, PLoS ONE)
  • "Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis" (2021, Hepatology Communications)
  • "Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)" (2023, Journal of Hepatology)
  • "Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study" (2021, The Lancet. Gastroenterology & hepatology)

Frequent co-authors collaborating with David E. Moller include:

  • Sophie Hallakou-Bozec
  • Sébastien Bolze
  • Pascale Fouqueray
  • Pascale Gluais Dagorn
  • Pierre-Axel Monternier

Key publication venues where David E. Moller has appeared are:

  • Journal of Hepatology
  • Diabetes Obesity and Metabolism
  • PLoS ONE
  • Hepatology Communications
  • The Lancet. Gastroenterology & hepatology

David E. Moller has been recognized as a member of the Association of American Physicians.

Best Publications

  • Role of AMP-activated protein kinase in mechanism of metformin action

    Gaochao Zhou;Robert Myers;Ying Li;Yuli Chen

  • The Mechanisms of Action of PPARs

    Joel Berger;David E. Moller

  • New drug targets for type 2 diabetes and the metabolic syndrome

    David E. Moller

  • Fibroblast growth factor 21 corrects obesity in mice.

    Tamer Coskun;Holly A. Bina;Michael A. Schneider;James D. Dunbar

  • Insulin resistance--mechanisms, syndromes, and implications.

    David E. Moller;Jeffrey S. Flier

  • Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.

    Nicolas Musi;Michael F. Hirshman;Jonas Nygren;Monika Svanfeldt

  • Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

    David E Moller

  • The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

    Gregory Gaich;Jenny Y. Chien;Haoda Fu;Leonard C. Glass

  • Metabolic syndrome: a clinical and molecular perspective.

    David E Moller;Keith D Kaufman

  • Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization

    Terry P. Combs;John A. Wagner;Joel Berger;Tom Doebber

  • Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

    A Vidal-Puig;M Jimenez-Liñan;B B Lowell;A Hamann

  • Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta.

    Hyunjung Lim;Rajnish A. Gupta;Wen Ge Ma;Bibhash C. Paria

  • Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.

    Bei Zhang;Gino Salituro;Deborah Szalkowski;Zhihua Li

  • Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

    James Mu;John Woods;Yun-Ping Zhou;Ranabir Sinha Roy

  • Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.

    Alex Elbrecht;Yuli Chen;Cathy A. Cullinan;Nancy Hayes

  • Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects

    Joel Berger;Mark D. Leibowitz;Thomas W. Doebber;Alex Elbrecht

  • Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

    Stacey L. Conarello;Zhihua Li;John Ronan;Ranabir Sinha Roy

  • Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha.

    Bei Zhang;Joel Berger;Et-ding Hu;Deborah Szalkowski

  • Differential Regulation of Glucose Transport and Transporters by Glucose in Vascular Endothelial and Smooth Muscle Cells

    Nurit Kaiser;Shlomo Sasson;Edward P Feener;Nizza Boukobza-Vardi

  • Evidence Against Altered Expression of GLUT1 or GLUT4 in Skeletal Muscle of Patients With Obesity or NIDDM

    Oluf Pedersen;Jens F Bak;Per H Andersen;Sten Lund

Frequent Co-Authors

Jeffrey S. Flier
Jeffrey S. Flier Harvard University
Samuel D. Wright
Samuel D. Wright CSL (United States)
Stephen O'Rahilly
Stephen O'Rahilly University of Cambridge
Roy G. Smith
Roy G. Smith Scripps Research Institute
Laurie J. Goodyear
Laurie J. Goodyear Harvard University
Antonio Vidal-Puig
Antonio Vidal-Puig University of Cambridge
Arthur A. Patchett
Arthur A. Patchett MSD (United States)
Philipp E. Scherer
Philipp E. Scherer The University of Texas Southwestern Medical Center
Nancy A. Thornberry
Nancy A. Thornberry MSD (United States)
Alexei Kharitonenkov
Alexei Kharitonenkov Indiana University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking flexible or alternative options to traditional medical school, online degrees can provide a valuable pathway. In the rapidly changing healthcare landscape, numerous accredited programs now allow you to study from anywhere and advance your career.

Aspiring advanced practice nurses may consider the cheapest dnp online programs for a cost-effective route to a Doctor of Nursing Practice degree. If your interests align with pharmaceuticals, pursuing an online pharmacy degree can open doors to hands-on and research-based roles in medication management.

Those drawn to the intersection of technology and healthcare will find valuable opportunities through online schools for health information management. This field is essential for maintaining and securing patient records. If you are seeking entry-level positions with rapid training, explore online medical billing and coding courses, which prepare you for vital roles in healthcare administration.

These online pathways can help you start or advance your career in medicine and healthcare—while offering flexible, affordable learning options.

Best Scientists Citing David E. Moller

Trending Scientists